000163861 001__ 163861
000163861 005__ 20240229123158.0
000163861 0247_ $$2doi$$a10.1002/ijc.33018
000163861 0247_ $$2ISSN$$a0020-7136
000163861 0247_ $$2ISSN$$a1097-0215
000163861 0247_ $$2altmetric$$aaltmetric:80386284
000163861 0247_ $$2pmid$$apmid:32319674
000163861 037__ $$aDKFZ-2020-02095
000163861 082__ $$a610
000163861 1001_ $$0P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aBoakye, Daniel$$b0$$eFirst author
000163861 245__ $$aBlood markers of oxidative stress are strongly associated with poorer prognosis in colorectal cancer patients
000163861 260__ $$aBognor Regis$$bWiley-Liss$$c2020
000163861 3367_ $$2DRIVER$$aarticle
000163861 3367_ $$2DataCite$$aOutput Types/Journal article
000163861 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1608117481_20752
000163861 3367_ $$2BibTeX$$aARTICLE
000163861 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163861 3367_ $$00$$2EndNote$$aJournal Article
000163861 500__ $$aInt. J. Cancer. 2020;147:2373–2386#EA:C070#LA:C070#
000163861 520__ $$aOxidative stress has been implicated in the initiation of several cancers, including colorectal cancer (CRC). Whether it also plays a role in CRC prognosis is unclear. We assessed the associations of two oxidative stress biomarkers (Diacron's reactive oxygen metabolites [d-ROMs] and total thiol level [TTL]) with CRC prognosis. CRC patients who were diagnosed in 2003 to 2012 and recruited into a population-based study in Germany (n = 3361) were followed for up to 6 years. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the associations of d-ROMs and TTL (measured from blood samples collected shortly after CRC diagnosis) with overall survival (OS) and disease-specific survival (DSS) were estimated using multivariable Cox regression. Particularly pronounced associations of higher d-ROMs with lower survival were observed in stage IV patients, with patients in the highest (vs lowest) tertile having much lower OS (HR = 1.52, 95% CI = 1.14-2.04) and DSS (HR = 1.61, 95% CI = 1.20-2.17). For TTL, strong inverse associations of TTL with mortality were observed within all stages. In patients of all stages, those in the highest (vs lowest) quintile had substantially higher OS (HR = 0.48, 95% CI = 0.38-0.62) and DSS (HR = 0.52, 95% CI = 0.39-0.69). The addition of these biomarkers to models that included age, sex, tumor stage and subsite significantly improved the prediction of CRC prognosis. The observed strong associations of higher d-ROMs and lower TTL levels with poorer prognosis even in stage IV patients suggest that oxidative stress contributes significantly to premature mortality in CRC patients and demonstrate a large potential of these biomarkers in enhancing the prediction of CRC prognosis beyond tumor stage.
000163861 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000163861 588__ $$aDataset connected to CrossRef
000163861 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1
000163861 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b2
000163861 7001_ $$aJansen, Eugene H. J. M.$$b3
000163861 7001_ $$0P:(DE-He78)0d37cc734b95fed555f2244d6fee6320$$aSchneider, Martin$$b4
000163861 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b5
000163861 7001_ $$0P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aGào, Xin$$b6
000163861 7001_ $$0P:(DE-HGF)0$$aChang‐Claude, Jenny$$b7
000163861 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$udkfz
000163861 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$eLast author
000163861 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.33018$$gVol. 147, no. 9, p. 2373 - 2386$$n9$$p2373 - 2386$$tInternational journal of cancer$$v147$$x1097-0215$$y2020
000163861 909CO $$ooai:inrepo02.dkfz.de:163861$$pVDB
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000163861 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)0d37cc734b95fed555f2244d6fee6320$$aExternal Institute$$b4$$kExtern
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000163861 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000163861 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163861 9141_ $$y2020
000163861 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-02-26$$wger
000163861 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2020-02-26$$wger
000163861 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2018$$d2020-02-26
000163861 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-02-26
000163861 9201_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x0
000163861 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000163861 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000163861 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000163861 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x4
000163861 980__ $$ajournal
000163861 980__ $$aVDB
000163861 980__ $$aI:(DE-He78)D240-20160331
000163861 980__ $$aI:(DE-He78)C070-20160331
000163861 980__ $$aI:(DE-He78)C120-20160331
000163861 980__ $$aI:(DE-He78)HD01-20160331
000163861 980__ $$aI:(DE-He78)C020-20160331
000163861 980__ $$aUNRESTRICTED